
News from bariatricnews.net
Media Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top bariatricnews.net News

Novo Nordisk · DenmarkNovo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive. The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen.See the Story
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects
76% Center coverage: 33 sources
Ascletis Begins Dosing in Phase IIa Trial of ASC30 for Obesity Treatment
62% Center coverage: 27 sources
Weight-Loss Injections Are Dominating the Market: Where Will GLP-1 Pills Fit in? | News Channel 3-12
73% Center coverage: 15 sources